Not only that, it's also illegal. No way Amgen would violate SEC rules to get ADXS for cheap. Amgen does not need to do anything -- they have been getting a major help from the third batch of Advaxis top management. All they need to do is sit tight and wait for the NEO results: they'll know if the data is great or not so great much sooner than anyone else. If they see the data is great, then they can just pull the trigger as the current market cap is so low, and they can afford to pay some premium to it. If data is just okay, they'll let their long term options expire...